Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy.
(2011) In Leukemia & Lymphoma 52 Suppl 2. p.46-49- Abstract
- Hairy cell leukemia is often reported as a disease of young males. The male predominance is strong, 4:1, but the median age in the Swedish national compulsory cancer registry is similar to that of follicular lymphoma, i.e. 62 years. The overall 6-year survival in the Swedish registry of patients diagnosed since 2000 is 80%, 93% of patients <60 years, and 68% of those >60 years. The yearly risk of secondary cancers is 1.75%. Cladribine is a prodrug which is selectively activated intracellularly. The intracellular initial half-life is 13 h and the terminal half-life is 30 h. Subcutaneous injection once daily is simple and effective due to 100% bioavailability and no local side effects from injection, and self-administration is easy.... (More)
- Hairy cell leukemia is often reported as a disease of young males. The male predominance is strong, 4:1, but the median age in the Swedish national compulsory cancer registry is similar to that of follicular lymphoma, i.e. 62 years. The overall 6-year survival in the Swedish registry of patients diagnosed since 2000 is 80%, 93% of patients <60 years, and 68% of those >60 years. The yearly risk of secondary cancers is 1.75%. Cladribine is a prodrug which is selectively activated intracellularly. The intracellular initial half-life is 13 h and the terminal half-life is 30 h. Subcutaneous injection once daily is simple and effective due to 100% bioavailability and no local side effects from injection, and self-administration is easy. Long-term follow-up of Scandinavian patients treated with cladribine (mostly as subcutaneous injections) in the early 1990s shows a >80% 15-year survival from cladribine treatment in <60 years of age, but <50% in older patients. Survival from diagnosis of these patients was similar for those previously treated and untreated. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1972197
- author
- Juliusson, Gunnar LU and Samuelsson, Henrik
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Leukemia & Lymphoma
- volume
- 52 Suppl 2
- pages
- 46 - 49
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000290869300012
- pmid:21599605
- scopus:79957492280
- pmid:21599605
- ISSN
- 1029-2403
- DOI
- 10.3109/10428194.2011.565842
- language
- English
- LU publication?
- yes
- id
- 85e7b455-bc4c-4e46-98c1-04551335948e (old id 1972197)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21599605?dopt=Abstract
- date added to LUP
- 2016-04-04 09:35:28
- date last changed
- 2022-08-23 07:52:06
@article{85e7b455-bc4c-4e46-98c1-04551335948e,
abstract = {{Hairy cell leukemia is often reported as a disease of young males. The male predominance is strong, 4:1, but the median age in the Swedish national compulsory cancer registry is similar to that of follicular lymphoma, i.e. 62 years. The overall 6-year survival in the Swedish registry of patients diagnosed since 2000 is 80%, 93% of patients <60 years, and 68% of those >60 years. The yearly risk of secondary cancers is 1.75%. Cladribine is a prodrug which is selectively activated intracellularly. The intracellular initial half-life is 13 h and the terminal half-life is 30 h. Subcutaneous injection once daily is simple and effective due to 100% bioavailability and no local side effects from injection, and self-administration is easy. Long-term follow-up of Scandinavian patients treated with cladribine (mostly as subcutaneous injections) in the early 1990s shows a >80% 15-year survival from cladribine treatment in <60 years of age, but <50% in older patients. Survival from diagnosis of these patients was similar for those previously treated and untreated.}},
author = {{Juliusson, Gunnar and Samuelsson, Henrik}},
issn = {{1029-2403}},
language = {{eng}},
pages = {{46--49}},
publisher = {{Taylor & Francis}},
series = {{Leukemia & Lymphoma}},
title = {{Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy.}},
url = {{http://dx.doi.org/10.3109/10428194.2011.565842}},
doi = {{10.3109/10428194.2011.565842}},
volume = {{52 Suppl 2}},
year = {{2011}},
}